erenumab
erenumab: developed by 1 company · 6 clinical trials tracked · 1 FDA decision.
erenumab evidence translation
What we can confirm
1 FDA record · 6 tracked trials
What it means
What to watch
Prepared research question
How could erenumab → AMGN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 2 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| AMGEN INC (AMGN) | Approved |
Clinical Trials (6)
Migraine Medication Effects on Urinary Symptoms
Primary endpoint: changes in OAB symptoms
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
Primary endpoint: Change in worst pain intensity for each drug sub-study
China HeadAche DIsorders RegiStry
Primary endpoint: Headache Days
A Multidisciplinary Translational Approach to Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache
Primary endpoint: Change in the Number of Days Experiencing Moderate-to-Severe Headaches
Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase 4 Study
Primary endpoint: Change From Baseline in Mean Monthly Hours of at Least Moderate Headache Pain Intensity Over Months 1, 2, and 3
Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain
Primary endpoint: Defense and Veterans Pain Rating Scale (DVPRS)
FDA Decisions1 records
Frequently asked questions
Who is developing erenumab?
erenumab is being developed by AMGEN INC.
How many clinical trials involve erenumab?
BioSniper tracks 6 clinical trials involving erenumab.
What is erenumab's latest FDA decision?
The most recent tracked FDA decision for erenumab is Approval for 1 INDICATIONS AND USAGE AIMOVIG is indicated for the preventive treatment of migraine in adults. AIMOVIG is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults. ( 1 ), dated May 17, 2018.